 BOSTON, April 28, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology ARVO Virtual Annual Meeting which is being held May 1-7, 2021. The poster showcases data that are consistent with elamipretides mechanism of action and provides further support for the companys design of ReCLAIM-2, Stealths Phase 2 trial focused on earlier stages of geographic atrophy which recently completed enrollment. 